MO25-3 Long time follow-up data of first-line pembrolizumab for advanced NSCLC patients with PD-L1 TPS of 50% or greaterYuichi Tambo,Takashi Sone,Kazuhiko Shibata,Kouichi Nishi,Hiroki Shirasaki,Taro Yoneda,Tomoyuki Araya,Kazumasa Kase,Shingo Nishikawa,Hideharu Kimura,Kazuo KasaharaAnnals of Oncology(2021)引用 0|浏览1暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要